The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

被引:45
|
作者
Davis, MP [1 ]
Homsi, J [1 ]
机构
[1] Cleveland Clin Fdn, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA
关键词
CYP2D6; palliative medicine; drug metabolism; drug interactions; ethnic differences; pharmacokinetics;
D O I
10.1007/s005200000222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enzymes in the cytochrome p450 monooxygenase system (CYP) are the major enzymes responsible for metabolizing medications. The CYP2D6 isomer is responsible for metabolizing certain opioids, neuroleptics, antidepressants and cardiac medications. Owing to CYP2D6's low capacity and high affinity it is easily saturated by substrate and/or inhibited, resulting in pharmacokinetic interactions. Polymorphisms of the structural gene are common, leading to wide inter-individual and ethnic differences in drug metabolism. Clinically important drug interactions, which may be anticipated in the palliative medicine population, are reviewed.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 50 条
  • [1] The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine
    Mellar P. Davis
    Jade Homsi
    Supportive Care in Cancer, 2001, 9 : 442 - 451
  • [2] Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10
    Dong, A. N.
    Ong, C. E.
    Pan, Y.
    Palanisamy, U. D.
    Ismail, R.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 49 - 49
  • [3] GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
    Neafsey, Patricia
    Ginsberg, Gary
    Hattis, Dale
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 334 - 361
  • [4] INHIBITION OF HUMAN CYTOCHROME P450 2D6 (CYP2D6) BY METHADONE
    WU, D
    OTTON, SV
    SPROULE, BA
    BUSTO, U
    INABA, T
    KALOW, W
    SELLERS, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (01) : 30 - 34
  • [5] Cytochrome p450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus
    Usia, T
    Watabe, T
    Kadota, S
    Tezuka, Y
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (06) : 1021 - 1024
  • [6] Intoxication with dextromethorphan in an adolescent with a genetic cytochrome P450 CYP2D6 deficiency
    Baumann, P
    Vlatkovic, D
    Macciardi, F
    THERAPIE, 1997, 52 (06): : 607 - 608
  • [7] Cytochrome P450 - CYP2D6 polymorphism in head and neck cancer patients
    Stefanovic, M
    Begonja, A
    Topic, E
    Curcic, I
    Simundic, A
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 110 - 111
  • [8] The involvement of CYP2D6 and other cytochrome P450 subfamilies in the metabolism of methylenedioxyamphetamines
    Kreth, KP
    Zanger, UM
    Schwab, M
    Kovar, KA
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R420 - R420
  • [9] Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping
    Streetman, DS
    Ellis, RE
    Nafziger, AN
    Leeder, JS
    Gaedigk, A
    Gotschall, R
    Kearns, GL
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (05) : 535 - 541
  • [10] Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan
    Abdul-Manap, R
    Wright, CE
    Rostami-Hodjegan, A
    Meller, S
    Lennard, MS
    Morice, AH
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 586 - 587